Xeloda, Capecitabine Newswire

Xeloda, Capecitabine Newswire

Comprehensive Real-Time News Feed for Xeloda, Capecitabine (generic).

Results 1 - 20 of 96 in Xeloda, Capecitabine (generic)

  1. Global Capecitabine Industry: Economical Impact, Development Trends and Growth RateRead the original story

    Sunday Jun 17 | Emailwire.com

    Capecitabine Market report provides details about production, revenue, gross margin, consumption value & volume, sale price, import and export, and forecast to 2023 Global Capecitabine Industry Report provides detailed analysis of the market structure along with forecast of the various segments and sub-segments. It also provides insights about factors affecting the market growth.

    Comment?

  2. Generic Product NewsRead the original story w/Photo

    May 22, 2018 | Pharmacy Times

    CAPECITABINE MARKETED BY: Aurobindo Pharma Ltd COMPARE TO: Xeloda INDICATION: The FDA has approved the abbreviated new drug application for capecitabine, which is indicated for the treatment of adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer. DOSAGE FORM: Tablets: 150 and 500 mg FOR MORE INFORMATION: aurobindo.com TIAGABINE HYDROCHLORIDE MARKETED BY: Amneal Pharmaceuticals COMPARE TO: Gabitril INDICATION: Amneal Pharmaceuticals has launched tiagabine hydrochloride tablets, an AB-rated therapeutic equivalent for Gabitril.

    Comment?

  3. Colorectal Colon Cancer Therapeutics Market 2025 - Current Perspectives & Future ProspectsRead the original story w/Photo

    Friday Jun 8 | SBWire

    Colorectal cancer, commonly known as colon cancer, rectal cancer, or bowel cancer, is the development of cancerous cells in the colon or rectum, which are the parts of large intestine. These cells are usually malignant in function and have the ability to spread to other organs of the body.

    Comment?

  4. New Treatment Combination Improves Outcomes for Some Patients with Colorectal CancerRead the original story

    Friday Jun 1 | PRWeb

    Reporting new research results at the ASCO Annual Meeting in Chicago, a research team from Roswell Park Comprehensive Cancer Center notes that the combination of nintedanib and capecitabine outperforms standard therapy as a treatment for advanced colorectal cancer. We're encouraged by this evidence that we were able to improve outcomes, especially in a notoriously hard-to-treat disease like refractory colorectal cancer .

    Comment?

  5. Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicityRead the original story w/Photo

    Friday May 25 | The Pharmacogenomics Journal

    Thank you for visiting nature.com. You are using a browser version with limited support for CSS.

    Comment?

  6. Therapy susceptible germline-related BRCA 1-mutation in a case of...Read the original story w/Photo

    Wednesday May 30 | BioMed Central

    Adenocarcinomas or combined adeno-neuroendocrine carcinomas of small bowel usually have a dismal prognosis with limited systemic therapy options. This is the first description of a patient showing a germline-related BRCA1 mutated MANEC of his ileum.

    Comment?

  7. Odonate Therapeutics Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingRead the original story w/Photo

    May 16, 2018 | The Galveston County Daily News

    May 16, 2018-- Odonate Therapeutics, Inc. , a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that there will be two poster presentations on tesetaxel at the 2018 American Society of Clinical Oncology Annual Meeting to be held June 1 - 5, 2018 in Chicago, Illinois. Abstracts for these presentations were made publicly available today and can be found on the ASCO website at http://abstracts.asco.org and by clicking the titles below.

    Comment?

  8. Korean Society of Coloproctology (KSCP) trial of cONsolidation...Read the original story w/Photo

    May 7, 2018 | BioMed Central

    Neoadjuvant chemoradiotherapy followed by total mesorectal excision has been a standard treatment option for locally advanced rectal cancer with improved local control. However, systemic recurrence despite neoadjuvant CRT remained unchanged.

    Comment?

  9. Therapeutic developments in pancreatic cancer: current and future perspectivesRead the original story w/Photo

    May 1, 2018 | Nature Reviews Gastroenterology and Hepatology

    Thank you for visiting nature.com. You are using a browser version with limited support for CSS.

    Comment?

  10. Your Daily Pharma Scoop: Blueprint Medicines' BLU-667, Gilead Sciences' NASH Data, Celldex's PlungeRead the original story w/Photo

    Apr 17, 2018 | Seeking Alpha

    The phase 1 study was a proof-of-concept study. Blueprint's BLU-667 is a highly selective inhibitor targeting oncogenic RET fusions and mutations, which are key drivers across multiple cancers, including subsets of patients with non-small cell lung cancer and medullary thyroid cancer .

    Comment?

  11. Celldex's lead candidate flunks breast cancer study; shares down 51% premarketRead the original story w/Photo

    Apr 16, 2018 | Seeking Alpha

    Celldex Therapeutics slumps 51% premarket on robust volume in response to its announcement that lead candidate glembatumumab vedotin , an antibody-drug conjugate, failed to demonstrate a treatment benefit over and above Roche's Xeloda in patients with triple-negative breast cancer that overexpress a protein called gpNMB. The Phase 2b trial, METRIC, failed to achieve the primary endpoint of a statistically valid improvement in progression-free survival .

    Comment?

  12. Celldex's METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary EndpointRead the original story

    Apr 16, 2018 | Customer Interaction Solutions

    Celldex Therapeutics, Inc. today reported that the Company's randomized, Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint, progression-free survival as assessed by an independent, central reading of patient scans . There was no significant advantage for glembatumumab vedotin in key secondary endpoints, including overall response rate, duration of response and overall survival.

    Comment?

  13. Updated Overall Survival Data for LYNPARZA (olaparib) in...Read the original story

    Apr 15, 2018 | Customer Interaction Solutions

    AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today presented data from the Phase III OlympiAD trial, showing the final overall survival results for LYNPARZA in metastatic breast cancer at the American Association for Cancer Research Annual Meeting in Chicago, April 14-18, 2018. with chemotherapy for patients with germline BRCA -mutated HER2-negative metastatic breast cancer and met its primary endpoint of progression-free survival .

    Comment?

  14. 3 Things In Biotech, April 3: Alkermes Gets Into Trouble, Puma Gets...Read the original story w/Photo

    Apr 4, 2018 | Seeking Alpha

    Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

    Comment?

  15. Influence of complete administration of adjuvant chemotherapy cycles...Read the original story w/Photo

    Apr 2, 2018 | BioMed Central

    A randomized trial demonstrated that capecitabine is at least as effective as fluorouracil in the adjuvant treatment of patients with locally advanced rectal cancer. However, not all patients receive all planned cycles of chemotherapy.

    Comment?

  16. Chemoradiotherapy versus chemotherapy as adjuvant treatment for...Read the original story w/Photo

    Apr 2, 2018 | BioMed Central

    Treatment of localized gastric cancer consists of surgical resection followed by adjuvant treatment. Both chemoradiation and chemotherapy regimens have shown benefit in survival outcomes versus observation.

    Comment?

  17. Laparoscopy-assisted colectomy as an Oncologically safe alternative...Read the original story w/Photo

    Apr 2, 2018 | BioMed Central

    It is still controversial whether laparoscopy-assisted colectomy is suitable for patients with stage T4 colon cancer. This study aimed to compare the short- and long-term outcomes of LAC and open colectomy for patients with pathologic T4 colon cancer.

    Comment?

  18. Colorectal Colon Cancer Therapeutics Market to Flourish with an Impressive CAGR by 2025Read the original story w/Photo

    Apr 3, 2018 | SBWire

    Colorectal cancer, commonly known as colon cancer, rectal cancer, or bowel cancer, is the development of cancerous cells in the colon or rectum, which are the parts of large intestine. These cells are usually malignant in function and have the ability to spread to other organs of the body.

    Comment?

  19. Duration of adjuvant chemotherapy for advanced colon cancerRead the original story

    Apr 3, 2018 | GastroHep.com

    This week's issue of the New England Journal of Medicine examines the duration of adjuvant chemotherapy for stage III colon cancer. Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer.

    Comment?

  20. The European Medicines Agency Accepts Regulatory Submission for...Read the original story

    Apr 3, 2018 | PressReleasePoint

    This is the first regulatory submission for a poly ADP-ribose polymerase inhibitor in breast cancer in Europe. If approved, the identification of a patient's BRCA status could become a critical step in the management of their disease alongside current consideration of their hormone receptor and HER2 status.

    Comment?